Candel director granted 32,000 stock options
Candel Therapeutics director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting ceasing if he leaves the board unless the board decides otherwise. After this grant, he holds 32,000 options directly.
Insider Trade Summary
Grant/Award: 32,000 shares
Grant/Award
1 txn
Insider
Martell Christopher
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,000 contracts (Direct)
Footnotes (1)
- F1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Key Figures
Options granted: 32,000 options
Exercise price: $9.08 per share
Expiration date: June 23, 2036
+3 more
6 metrics
Options granted
32,000 options
Grant to director Christopher Martell for Common Stock
Exercise price
$9.08 per share
Strike price of newly granted stock options
Expiration date
June 23, 2036
Option term end date
Underlying shares
32,000 shares
Common Stock underlying the options
Vesting date trigger
Earlier of June 23, 2027 or next Annual Meeting
Time-based vesting condition
Post-grant derivative holdings
32,000 options
Total options held directly after this grant
Key Terms
Stock Option (Right to Buy), time-based vesting, Annual Meeting of Stockholders, Common Stock, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
time-based vesting financial
"This option is subject to time-based vesting."
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Board of Directors financial
"resigns from the Board of Directors (the "Board") of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Candel Therapeutics (CADL) report for Christopher Martell?
Candel Therapeutics reported that director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock. This is a compensation-related award, not an open-market purchase or sale of existing CADL shares.
What is the exercise price and size of Christopher Martell’s new CADL stock options?
Christopher Martell was granted options covering 32,000 shares of Candel Therapeutics Common Stock at an exercise price of $9.08 per share. These options give him the right to buy shares at that fixed price if and when they vest.
When do Christopher Martell’s Candel Therapeutics (CADL) options vest?
The 32,000 options granted to Christopher Martell vest on the earlier of June 23, 2027 or the date of Candel Therapeutics’ next Annual Meeting of Stockholders. Vesting stops if he ceases serving as a director, unless the board decides to continue vesting.
When do the newly granted CADL stock options to Christopher Martell expire?
The stock options granted to Christopher Martell expire on June 23, 2036. If the options have vested by then, he must exercise them before that expiration date; otherwise, any unexercised portion will lapse and become worthless.
How many Candel Therapeutics options does Christopher Martell hold after this Form 4?
Following this grant, Christopher Martell holds 32,000 stock options directly. These options relate to an equal number of Candel Therapeutics Common Stock shares and are subject to the vesting and expiration terms disclosed in the filing’s footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates